Objective. To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Patients and Methods. Eight hundred and sixty-six rheumatology and internal medicine practitioners were contacted by E-mail to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated.
After decades during which the T cell was considered the cornerstone of autoimmunity, interest has recently grown in the pivotal role of B cells in autoantibody secretion, autoantigen presentation (1), pro-inflammatory cytokine production (2) and regulation of dendritic cell function (3) . Thus, rituximab, a chimeric monoclonal antibody specific for human CD20, which targets B lymphocytes, could be a potential new biological treatment of autoimmune diseases. To date, rheumatoid arthritis (RA) is the only disease in which efficacy of rituximab was demonstrated in a controlled trial (4) . Because rituximab received marketing authorization for lymphoma and despite the absence of marketing authorization in autoimmune diseases, some clinicians have already started to use it to treat refractory autoimmune diseases.
The Club Rhumatismes et Inflammation (CRI), a section of the Société Française de Rhumatologie, has 866 members from approximately 100 departments of rheumatology and internal medicine registered on its Web site, which allows for collecting reliable data on practice in France regarding autoimmune diseases. The present retrospective study was initiated by the CRI to evaluate the safety and efficacy of rituximab in patients with diverse autoimmune diseases.
PATIENTS AND METHODS Patient selection
Eight hundred and sixty-six rheumatology and internal medicine practitioners registered on the Web site of CRI were contacted 4 times by E-mail to obtain the files of patients treated with rituximab for the following systemic autoimmune diseases: RA, systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSS) and vasculitis. The charts were reviewed by 2 of the authors (XM and JEG). The diagnoses were re-assessed by use of international consensus criteria (American College of Rheumatology for RA, SLE and vasculitis and the European-American consensus group criteria for pSS). Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. It was ensured that each patient whithout lymphoma had been informed that the treatment was experimental and had not received marketing authorization in autoimmune diseases. After these detailed explanations, each patient gave informed consent for treatment with rituximab.
Treatment
The number of rituximab infusions, as well as the dosage and rhythm of infusion, was recorded in each patient. Concomitant medications, including immunosuppressant agents and prednisone, were noted.
Assessment
Tolerance and adverse events were recorded for each patient. Disease activity score 28 (DAS28) and SLE disease activity index (SLEDAI) values were recorded in patients with RA and SLE, respectively. In patients with RA or SLE, efficacy was defined as a decrease of 50% (partial remission [PR]) or more of the initial DAS28 and SLEDAI values, respectively. Patients with RA and a DAS value below 2.6 were considered to be in complete remission (CR) as well as patients with SLE and a SLEDAI value between 0 and 2. In patients with other autoimmune diseases, efficacy was defined as a decrease of 50% (PR) or more of the initial disease activity according to the clinician in charge of the patient. Patients with other autoimmune diseases, in whom all symptoms and clinical features disappeared, were considered to be in CR.
RESULTS

Patient characteristics
Twenty-four departments of rheumatology and internal medicine had patients treated with rituximab for autoimmune diseases. Forty-nine observations were collected. Six were excluded because of diagnosis uncertainty (n = 3) or inability to evaluate the course of the autoimmune disease in patients with lymphoma (n = 3). Thus, 43 observations could be analysed. The clinical characteristics of the 43 patients are reported in Tables 1-5. The study included 14 patients with RA, 13 with SLE, 6 with pSS, 5 with systemic vasculitis and 5 with other inflammatory arthritides. (antisynthetase syndrome [n = 2], systemic sclerosis [n = 1], Still's disease [n = 1], sarcoidosis [n = 1]). Rituximab was prescribed for lymphoma associated with autoimmune disease in 2 patients with RA and 2 with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. Nine patients with RA had previously been treated with anti-TNF, 7 SLE patients with cyclophosphamide, 2 type II mixed cryoglobulinemia patients with interferon and ribavirin and 3 patients with vasculitis had not responded to cyclophosphamide and infliximab.
Characteristics of rituximab administration and concomitant medications
Thirty-five patients received weekly infusions of 375 mg/m 2 of rituximab for 4 weeks, 5 patients were given 2 infusions of 1000 mg, and a different dosage regimen was followed in 3 patients (patients 3, 5 and 38, Tables 1 and 4 ). Rituximab was given in combination with methotrexate (MTX) in 6 patients, with other immunosuppressants in 15 patients, with pulses of methylprednisolone in 7 patients and prescribed alone in 15 patients (Tables 1-5 ). The mean follow-up period was 8.3 months (2-26 months).
Tolerance and safety
Eleven adverse events were observed in 10 patients. Infusion-related reactions, such as transient hypo-or hypertension, were observed in 3 patients (patients 10, 33 and 35). These infusion-related reactions occurred during the first infusion in 2 patients (patients 10 and 33), who had experienced prior infusion-related reactions with infliximab, and during the seventh infusion (third infusion after clinical relapse) in the other (patient 35). In one patient with chronic hepatitis C (patient 34) and renal function impairment (creatinine clearance of 35 mL/mn), 2 repeated episodes of encephalopathy developed 2 days after the second and third infusion, concomitantly with hyperammonemia (2.18 and 4.17 mg/L, respectively, N<0.8 mg/L). This patient had histologic features of chronic hepatitis, without cirrhosis. Two patients with SLE (patients 22 and 24) and one with pSS (patient 29) had serum sickness-like reactions (urticaria, arthralgias within 2 days after the first and third infusions (patient 22) and after each infusion (patients 24 and 29)). In 1 patient with SLE-related end-stage renal disease requiring hemodialysis (patient 15), severe sepsis-like syndrome along with neutropenia (blood neutrophil count 0.6 x 10 9 /L) developed 10 days after a 500-mg infusion of rituximab. One patient with SLE had neutropenia (blood neutrophil count 0.7 x 10 9 /L) 15 days after the first infusion of rituximab (patient 26). Mycophenolate mofetil, which had been given concomitantly (1.5 g/day), was discontinued, and the blood neutrophil count returned to within the normal range. Two patients with SLE, including 1 with nephrotic syndrome (patient 21), developed deep vein thrombosis, with pulmonary embolism in 1 (patient 22), 5 and 4 months, respectively, after treatment with rituximab. Both patients had IgG anticardiolipin antibodies.
Treatment was discontinued in 6 of these 11 patients. Late-onset neutropenia and marked hypogammaglobulinemia were not observed, but serum gammaglobulin levels were monitored in only 21 patients. Liver enzyme levels were initially 1.5 and 2 as high as normal in 2 patients with hepatitis C viral (HCV) replication (patients 34 and 35) and did not significantly change after rituximab therapy. Liver enzyme levels remained within the normal range in the other patients.
Short-term efficacy of anti-CD20 therapy
Efficacy of rituximab was observed in 30 patients (70%), including 11 RA, 9 SLE, 5 pSS, 2 vasculitis, 2 antisynthetase syndromes and 1 sarcoidosis. Efficacy was observed in 17 of these patients not concomitantly with DMARDs/immunosuppressants, 5 with MTX and 8 with other DMARDS/immunosuppressants. Mean time to response was 5.4 weeks (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The mean decrease of daily corticosteroid dose was 9.5 mg/day (0-50) in patients who responded to rituximab. Oral corticosteroids could be discontinued in 4 patients (patients 5,12, 31 and 33). Seven patients, including 5 patients treated with rituximab alone (patients 2, 16, 35, 39 and 41) and 2 patients treated with MTX and cyclosporin (patients 3 and 23, respectively), experienced relapse after 8.1 months (5-15), on average. Four patients were retreated with rituximab, but the current follow-up is not sufficient to evaluate the clinical evolution of these patients. Three patients died because of refractory autoimmune disease (rheumatoid vasculitis, refractory autoimmune haemolytic anaemia in a SLE patient and refractory cerebral vasculitis in another SLE patient). (Table 1) . Eleven of 14 patients with RA responded to rituximab, including 4 patients in complete remission (DAS28 < 2.6) and 7 patients in partial remission (decrease of 50% or more of the initial DAS28). The mean DAS28 decreased from 6.7±1.3 (5.3-8.7) to 3.4±1.4 (1.8-6.7) (P < 0.0002 using paired t-test). In 11 responders, the mean daily dosage of prednisone decreased from 9.3 mg (0-20) to 5.9 mg (0-10) (P < 0.01) after a mean follow-up duration of 8.6 months (2-24). Rheumatoid factor values, evaluated in 8 RF-positive patients, decreased in 6 patients ( Table 1) . Table 2) . Nine of 13 patients with SLE responded to rituximab, including 7 patients in complete remission (SLEDAI value between 0 and 2) and 2 patients in partial remission (decrease of 50% or more of the initial SLEDAI). Two patients died because of the refractory character of the autoimmune disease. Two of the 4 SLE patients with active nephritis and 7 of the 9 patients without nephritis responded to rituximab. The mean SLEDAI value decreased from 11±7 (3-28) to 5±6 (0-20) in the 11 surviving patients (P < 0.0002 using paired t-test). For the 9 responders, the mean daily dosage of prednisone decreased from 27 mg (5-60) to 8 mg (2-13) (P < 0.01), after a mean follow-up duration of 9.8 months (4-26). The variation in the level of anti-double-stranded DNA antibody was different in individual patients ( Table 2) . (Table 3 ). The efficacy of rituximab and partial remission were observed in 5 of 6 patients, with regression of parotid swelling, articular involvement, subjective dryness and fatigue in 2 patients (patients 32 and 33), improvement of subjective dryness in 1 (patient 28), and major improvement of cryoglobulinemia-related vasculitis in 2 (patients 30 and 31), with concomitant disappearance of cryoglobulinemia. In 1 patient with salivary lymphoma of the MALT subset (patient 29), therapy with rituximab was not successful. Regarding glandular symptoms, self-reported dryness was improved in only 3 patients (patients 28, 32 and 33) and was not changed in the 3 others, whereas objective ocular and mouth dryness, assessed in only patients 28 and 30, was not improved. RF levels decreased in the 3 responders in whom it was assessed but did not decrease in the patient, who was non responder to rituximab (Table 3 ). In all patients with anti-SSA/SSB antibodies (4 patients with anti-SSA antibody, 2 with anti-SSB), these autoantibodies remained detectable after rituximab. (Table 4 ). Efficacy of rituximab was observed in 2 of 5 patients, in whom partial remission was obtained. One patient with rheumatoid vasculitis died 6 weeks after rituximab because of acute respiratory distress syndrome, which was not due to alveolar hemorrhage (patient 36). One patient with cirrhosis, treated with rituximab for HCV-related type II mixed cryoglobulinemia, healed from skin ulcers and had no detectable cryoglobulinemia 5 months after the last infusion (patient 35). Peripheral nerve and renal involvement remained stable despite rituximab. The mixed cryoglobulinemia reappeared 7 months after the last infusion of rituximab, and the patient experienced a clinical relapse (purpura flares) 5 months later. One patient with Wegener's granulomatosis (patient 38), who had been non responder to MTX and mycophenolate mofetil (MMF), experienced a marked response to rituximab: ear, nose and throat involvement was stabilized, and a concomitant pyoderma gangrenosum was markedly improved. Anti-proteinase 3 antibody, determined by ELISA (initial serum level of 90 IU), disappeared within 6 months of treatment. (Table 5 ). Polymyositis was greatly improved in 2 patients treated with rituximab for antisynthetase syndrome (patients 39 [partial remission] and 40 [complete remission]). The creatine kinase (CK) level of patient 39 decreased from 252 to 119 IU/L (N <150). This patient, treated with rituximab alone, also experienced good improvement of pemphigus-associated lesions; mucosal lesions disappeared, and skin lesions were markedly reduced. The CK level of patient 40 decreased from 1364 to 93 IU/L (N<160) and serum aldolase decreased from 25 to 8 (N<7.5). Muscle strength normalised in this patient, allowing for a marked decrease of daily prednisone. The patient was able to go back to work 4 months after rituximab therapy. Anti-Jo1 antibody remained detectable in both patients.
Patients with RA
Patients with SLE (
Patients with pSS
Patients with vasculitis
Patients with other inflammatory arthritides
Rituximab alone had a dramatic clinical effect on cervical lymphadenopathy as well as a clear corticosteroid sparing effect in 1 patient with lymph node sarcoidosis (patient 41), who achieved CR after treatment.
No efficacy of rituximab was observed in 1 patient treated with rituximab and cyclophosphamide for severe Still's disease and polysynovitis (patient 42). Rituximab and fludarabin had no effect on the clinical course of systemic sclerosis in 1 patient who had previously experienced relapse after high-dose cyclophosphamide and autologous stem-cell transplantation (patient 43).
Monitoring of B cell depletion
B-cell depletion (defined as a peripheral CD19+ B lymphocyte count < 5 cells/µl), which was assessed in only 12 patients, was observed in all but 1 patient, in whom rituximab therapy was unsuccessful (patient 29). Two of the 11 remaining patients, whose B-cell pool was depleted, did not respond to rituximab (patients 13 and 17).
Monitoring of HCV load
Three patients had antibodies against hepatitis C, including 2 with cryoglobulinemia-related vasculitis (patients 34 and 35) and 1 with SLE (patient 22). HCV load was not detectable in patient 22 before treatment and remained undetectable after rituximab. In the two patients with cryoglobulinemia, HCV viral load increased shortly after rituximab and then returned to base line (Table 4 ).
DISCUSSION
This retrospective study demonstrates that despite the absence of marketing authorization, rituximab is used in various refractory autoimmune diseases in daily rheumatological practice. The use of rituximab for off-label autoimmune diseases might even be more frequent, since this retrospective study depended on the recall of clinicians to accure cases. Short-term efficacy could be observed in 70% of patients. Additionally, rituximab therapy allowed for a reduction of oral corticosteroids by 9.5 mg/day, on average, in responders. Limitations to this retrospective study include the heterogeneity of the diseases studied and the rather short follow-up duration, which prevents from drawing definite conclusions regarding the long-term efficacy of rituximab. This led us to concentrate mainly on the tolerance of rituximab in these 43 patients with autoimmune diseases.
Tolerance of rituximab was good and in accordance with data from the literature. Interestingly, 2 patients (patients 10 and 35) with infusion-related reactions experienced the same side effects with infliximab, another chimeric monoclonal antibody. In these patients, a cross-allergy to the mice component could be hypothesized. The 2 patients, who experienced the most severe side effects (encephalopathy and sepsis-like syndrome), had renal function impairment. Serum sickness-like reactions, which occurred repeatedly in 3 patients have been described in patients treated with rituximab (5-7). The 3 deaths appeared to be a consequence of the refractory character of the autoimmune disease and not to intolerance of rituximab.
The main experience of rituximab in autoimmune diseases comes from a controlled trial in RA (4) . In that study, 43% (rituximab and MTX) and 41% (rituximab and cyclophosphamide) of patients with RA achieved 50% improvement according to the ACR criteria, compared with 13% of patients given MTX alone. Our results compare well with that of the controlled trial, showing comparable efficacy and tolerance of rituximab in patients not under trial conditions, including 9 patients in failure of anti-TNF therapy.
The first published open study (8) of SLE included 6 patients with severe SLE treated with rituximab, high-dose steroids and cyclophosphamide, which led to clinical improvement in 5 patients. The same group reported the results of 6 patients with nephritis: four of them experienced a marked improvement of lupus activity and of serologic and renal features (9) . Recently, another group reported the efficacy of rituximab added to current therapy in 18 patients (10) . Clinical activity of lupus markedly decreased in 10 patients in whom B cells were depleted. No overall change in serum levels of anti-dsDNA antibodies was observed. A few case reports exist of treatment with rituximab for autoimmune hemolytic anemia (11), thrombocytopenia (12), and neurological involvement with secondary anti-phospholipid syndrome (13) in patients with SLE.
In the present study, two of the 4 SLE patients with active nephritis and 7 of the 9 without nephritis responded to rituximab. These results suggest the potential use of rituximab in severe SLE, since 2 of 4 patients with lupus nephritis and 1 patient with central nervous system involvement were greatly improved. Additionally, rituximab had a marked corticosteroid sparing effect in milder but corticodependent forms of lupus with cutaneous or articular involvement, since it allowed for decreasing the daily prednisone dosage in responders by more than 3 times on average. No conclusion regarding the effect of rituximab on anti-dsDNA level can be drawn given the limited number of patients assessed.
In pSS, the first published observation described self-reported subjective improvement of oral and ocular dryness in pSS following therapy with rituximab for parotid marginal zone lymphoma (14) . Recently, the clinical evolution of 4 patients treated with rituximab for pSS-associated lymphoma was reported (15) . Type II mixed cryoglobulinemia (MC), observed in 3 patients, disappeared. No information was given concerning the evolution of sicca syndrome. In the present study, extraglandular symptoms, notably swelling of the parotid gland, arthralgias, and cryoglobulinemia-related vasculitis, were sensitive to rituximab in all but 1 patient. Decrease in level of RF and/or cryoglobulinemia accompanied clinical improvement of extraglandular signs in responders. However, no conclusion can be drawn regarding the effect of rituximab on dryness.
For patients with vasculitis and HCV-related type II MC, the largest experience comes from 2 Italian studies, involving 15 and 20 patients each (16, 17) . A significant increase in level of HCV RNA was observed in responders in 1 of the series, as in 2 of our patients (including 1 responder). Thus, the association of anti-viral therapy to rituximab could be considered in patients with replicating hepatitis C. The present study involved 4 patients with cryoglobulinemia (2 HCV-related, 2 pSS-related). Rituximab had a great effect on purpura and skin ulcers in 3 patients and peripheral nerve involvement in 2. Cryoglobulinemia disappeared in the 3 responders. Concerning ANCA-related vasculitis, only 1 case of Wegener's granulomatosis (WG), with good response to rituximab in combination with cyclophosphamide and highdose steroids, was reported (18) . The present study involved 2 patients with WG, in whom treatment with CPH had been unsuccessful. Only one patient responded well to rituximab, with a concomitant marked improvement of pyoderma gangrenosum and disappearance of anti-proteinase 3 antibody.
Clinicians involved in the study also used rituximab for other inflammatory arthritides such as antisynthetase syndrome, sarcoidosis, systemic sclerosis and Still's disease, for which no case reports have been reported. Rituximab could be a promising therapeutic strategy in antisynthetase syndrome, since it normalized muscular strength and muscle enzyme levels and reduced corticosteroid dosage in our 2 patients. Likewise, rituximab has shown good efficacy in 5 patients with refractory dermatomyositis (19) . Efficacy of rituximab in sarcoidosis, observed in 1 patient, also requires further study.
Interestingly, almost half of the responders received rituximab concomitantly with immunosuppressants. Among the 7 patients who experienced clinical relapse of the disease, 5 patients had taken rituximab alone. Thus, in autoimmune diseases, combination therapy might improve the efficacy of rituximab, as demonstrated in RA (4), and might delay the occurrence of relapses.
B-cell count decrease paralleled clinical efficacy in 9 patients and was stable in 1 patient in whom therapy with rituximab was unsuccessful. In patients who experience relapse, clinical manifestation of disease is often preceded by the reappearance of B cells and/or autoantibodies (20) , which could be observed in 3 patients (reappearance of B cells in 1 patient with SLE, of anti-dsDNA antibodies in another patient with SLE and of cryoglobulinemia in 1 patient with HCV-related vasculitis).
This study showed good tolerance, short-term clinical efficacy and marked reduction in corticosteroid use with rituximab treatment in patients with various refractory autoimmune diseases. Controlled trials should be carried out to demonstrate the therapeutic effect of rituximab in SLE, pSS, vasculitis and polymyositis. : evolution of neutropenia of patients of 13 and 14 was described in a submitted case report. 2 : P < 0.0002 between DAS28 value pre and post treatment using paired t-test. 3 : P < 0.01 between prednisone dose pre and post treatment. : P < 0.0002 between SLEDAI value pre and post treatment using paired t-test. 2 : P < 0.01 between prednisone dose pre and post treatment. 
